{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:38Z","timestamp":1792791458241,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81371731"],"award-info":[{"award-number":["No. 81371731"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital Medical Research and Development Fund","award":["No. 2016-4-40112"],"award-info":[{"award-number":["No. 2016-4-40112"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10067-018-4083-5","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:28:22Z","timestamp":1522715302000},"page":"53-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Paradoxical skin lesions induced by anti-TNF-\u03b1 agents in SAPHO syndrome"],"prefix":"10.1007","volume":"38","author":[{"given":"Chen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"issue":"3","key":"4083_CR1","first-page":"187","volume":"54","author":"A Chamot","year":"1987","unstructured":"Chamot A, Benhamou C, Kahn M, Beraneck L, Kaplan G, Prost A (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Revue du rhumatisme et des maladies ost\u00e9o-articulaires 54(3):187\u2013196","journal-title":"Revue du rhumatisme et des maladies ost\u00e9o-articulaires"},{"issue":"5","key":"4083_CR2","doi-asserted-by":"publisher","first-page":"R140","DOI":"10.1186\/ar2812","volume":"11","author":"G Assmann","year":"2009","unstructured":"Assmann G, Kueck O, Kirchhoff T, Rosenthal H, Voswinkel J, Pfreundschuh M, Zeidler H, Wagner AD (2009) Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Arthritis Res Ther 11(5):R140","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"4083_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/rheumatology\/keh149","volume":"43","author":"H Amital","year":"2004","unstructured":"Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A (2004) SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 43(5):658\u2013661. https:\/\/doi.org\/10.1093\/rheumatology\/keh149","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4083_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0049-0172(99)80027-4","volume":"29","author":"G Hayem","year":"1999","unstructured":"Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, Kahn MF, Meyer O (1999) SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 29(3):159\u2013171","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"4083_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/ar2837","volume":"11","author":"AP Rozin","year":"2009","unstructured":"Rozin AP (2009) SAPHO syndrome: is a range of pathogen-associated rheumatic diseases extended. Arthritis Res Ther 11(6):131","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"4083_CR6","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3899\/jrheum.091086","volume":"37","author":"K Ben Abdelghani","year":"2010","unstructured":"Ben Abdelghani K, Dran DG, Gottenberg JE, Morel J, Sibilia J, Combe B (2010) Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 37(8):1699\u20131704. https:\/\/doi.org\/10.3899\/jrheum.091086","journal-title":"J Rheumatol"},{"issue":"1 Suppl","key":"4083_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03946320140270S101","volume":"27","author":"C Blandizzi","year":"2014","unstructured":"Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Girolomoni G (2014) The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 27(1 Suppl):1\u201310. https:\/\/doi.org\/10.1177\/03946320140270S101","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6","key":"4083_CR8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/rheumatology\/kei221","volume":"45","author":"A Massara","year":"2006","unstructured":"Massara A, Cavazzini P, Trotta F (2006) In SAPHO syndrome anti-TNF-\u03b1 therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 45(6):730\u2013733","journal-title":"Rheumatology"},{"issue":"3","key":"4083_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","volume":"156","author":"HH Lee","year":"2007","unstructured":"Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, R\u00f6wert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156(3):486\u2013491. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07682.x","journal-title":"Br J Dermatol"},{"issue":"3","key":"4083_CR10","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","volume":"7","author":"M Flendrie","year":"2005","unstructured":"Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL (2005) Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 7(3):R666\u2013R676. https:\/\/doi.org\/10.1186\/ar1724","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"4083_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/rheumatology\/kew015","volume":"55","author":"C Li","year":"2016","unstructured":"Li C, Zuo Y, Wu N, Li L, Li F, Zhang W, Xu W, Zhao X, Jing H, Pan Q, Zhou W, Shi X, Fan Y, Wang J, Liu S, Liu Z, Zhang F, Zeng X, Chen H, Zhang S, Liu J, Qiu G, Wu Z, Dong Z, Zhang W (2016) Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patients. Rheumatology (Oxford) 55(6):1023\u20131030. https:\/\/doi.org\/10.1093\/rheumatology\/kew015","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4083_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/s0950-3579(94)80022-7","volume":"8","author":"M-F Kahn","year":"1994","unstructured":"Kahn M-F, Khan MA (1994) The SAPHO syndrome. Bailli\u00e8re\u2019s Clin Rheum 8(2):333\u2013362. https:\/\/doi.org\/10.1016\/s0950-3579(94)80022-7","journal-title":"Bailli\u00e8re\u2019s Clin Rheum"},{"issue":"1","key":"4083_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13058-015-0538-7","volume":"17","author":"HA Azim Jr","year":"2015","unstructured":"Azim HA Jr, Peccatori FA, Brohee S et al (2015) RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 17(1):24. https:\/\/doi.org\/10.1186\/s13058-015-0538-7","journal-title":"Breast Cancer Res"},{"issue":"7","key":"4083_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1346-8138.2007.00312.x","volume":"34","author":"H Takahashi","year":"2007","unstructured":"Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H (2007) Psoriasiform and pustular eruption induced by infliximab. J Dermatol 34(7):468\u2013472. https:\/\/doi.org\/10.1111\/j.1346-8138.2007.00312.x","journal-title":"J Dermatol"},{"issue":"10","key":"4083_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","volume":"7","author":"G Mocci","year":"2013","unstructured":"Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L (2013) Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis 7(10):769\u2013779. https:\/\/doi.org\/10.1016\/j.crohns.2013.01.009","journal-title":"J Crohns Colitis"},{"issue":"3","key":"4083_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","volume":"40","author":"AN Collamer","year":"2010","unstructured":"Collamer AN, Battafarano DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40(3):233\u2013240. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.04.003","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"4083_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","volume":"63","author":"C Tillack","year":"2014","unstructured":"Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut 63(4):567\u2013577","journal-title":"Gut"},{"issue":"2","key":"4083_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/09546630802441234","volume":"20","author":"JM Ko","year":"2009","unstructured":"Ko JM, Gottlieb AB, Kerbleski JF (2009) Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 20(2):100\u2013108. https:\/\/doi.org\/10.1080\/09546630802441234","journal-title":"J Dermatol Treat"},{"issue":"2","key":"4083_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","volume":"76","author":"G Brown","year":"2017","unstructured":"Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, Linos E, Liao W, Haemel A (2017) Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol 76(2):334\u2013341. https:\/\/doi.org\/10.1016\/j.jaad.2016.08.012","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4083_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/DAD.0b013e3181cb3ff7","volume":"32","author":"AC Laga","year":"2010","unstructured":"Laga AC, Vleugels RA, Qureshi AA, Velazquez EF (2010) Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol 32(6):568\u2013573. https:\/\/doi.org\/10.1097\/DAD.0b013e3181cb3ff7","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"4083_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","volume":"22","author":"I Guerra","year":"2016","unstructured":"Guerra I, P\u00e9rez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, Chaparro M, Ma\u00f1osa M, Hinojosa E, Minguez M, Ortiz de Zarate J, M\u00e1rquez L, Prieto V, Garc\u00eda-S\u00e1nchez V, Guardiola J, Rodriguez GE, Mart\u00edn-Arranz MD, Garc\u00eda-Tercero I, Sicilia B, Masedo \u00c1, Lorente R, Rivero M, Fern\u00e1ndez-Salazar L, Guti\u00e9rrez A, van Domselaar M, L\u00f3pez-SanRom\u00e1n A, Ber Y, Garc\u00eda-Sepulcre M, Ramos L, Bermejo F, Gisbert JP, Spanish GETECCU group (ENEIDA project) (2016) Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 22(4):894\u2013901","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"4083_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","volume":"161","author":"J Seneschal","year":"2009","unstructured":"Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taieb A (2009) Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 161(5):1081\u20131088. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09329.x","journal-title":"Br J Dermatol"},{"issue":"12","key":"4083_CR23","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67(12):1670\u20131677. https:\/\/doi.org\/10.1136\/ard.2007.077974","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4083_CR24","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1097\/MIB.0000000000000198","volume":"20","author":"M Friedrich","year":"2014","unstructured":"Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S (2014) IL-36\u03b3 sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn\u2019s disease. Inflamm Bowel Dis 20(11):1891\u20131901","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"4083_CR25","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","volume":"190","author":"A Johnston","year":"2013","unstructured":"Johnston A, Fritz Y, Dawes SM, Diaconu D, al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, Ward NL (2013) Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol 190(5):2252\u20132262. https:\/\/doi.org\/10.4049\/jimmunol.1201505","journal-title":"J Immunol"},{"issue":"10","key":"4083_CR26","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1517\/13543784.2015.1076793","volume":"24","author":"M Campa","year":"2015","unstructured":"Campa M, Ryan C, Menter A (2015) An overview of developing TNF-alpha targeted therapy for the treatment of psoriasis. Expert Opin Investig Drugs 24(10):1343\u20131354. https:\/\/doi.org\/10.1517\/13543784.2015.1076793","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"4083_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semarthrit.2007.05.004","volume":"37","author":"B Grinblat","year":"2008","unstructured":"Grinblat B, Scheinberg M (2008) The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 37(4):251\u2013255","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"4083_CR28","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"P Charles","year":"1999","unstructured":"Charles P, Elliott MJ, Davis D et al (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163(3):1521\u20131528","journal-title":"J Immunol"},{"issue":"6","key":"4083_CR29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","volume":"10","author":"K Lis","year":"2014","unstructured":"Lis K, Kuzawinska O, Balkowiec-Iskra E (2014) Tumor necrosis factor inhibitors\u2014state of knowledge. Arch Med Sci 10(6):1175\u20131185. https:\/\/doi.org\/10.5114\/aoms.2014.47827","journal-title":"Arch Med Sci"},{"issue":"17","key":"4083_CR30","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.3748\/wjg.v20.i17.5031","volume":"20","author":"E Pallagi-Kunstar","year":"2014","unstructured":"Pallagi-Kunstar E, Farkas K, Szepes Z et al (2014) Utility of serum TNF-alpha, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 20(17):5031\u20135035. https:\/\/doi.org\/10.3748\/wjg.v20.i17.5031","journal-title":"World J Gastroenterol"},{"issue":"4","key":"4083_CR31","first-page":"469","volume":"23","author":"AF Edrees","year":"2005","unstructured":"Edrees AF, Misra SN, Abdou NI (2005) Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 23(4):469\u2013474","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"4083_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jbspin.2015.09.004","volume":"83","author":"S Alonso","year":"2016","unstructured":"Alonso S, Tejon P, Sarasqueta C, Coto P, Alperi M, Queiro R (2016) Age at disease onset may help to further characterize the disease phenotype in psoriatic arthritis. Joint Bone Spine 83(5):533\u2013537. https:\/\/doi.org\/10.1016\/j.jbspin.2015.09.004","journal-title":"Joint Bone Spine"},{"issue":"7","key":"4083_CR33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/rheumatology\/ket363","volume":"53","author":"R Queiro","year":"2014","unstructured":"Queiro R, Tejon P, Alonso S, Coto P (2014) Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology (Oxford, England) 53(7):1178\u20131185. https:\/\/doi.org\/10.1093\/rheumatology\/ket363","journal-title":"Rheumatology (Oxford, England)"},{"issue":"3","key":"4083_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","volume":"13","author":"T Henseler","year":"1985","unstructured":"Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13(3):450\u2013456","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4083_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jbspin.2011.02.009","volume":"78","author":"R Queiro","year":"2011","unstructured":"Queiro R, Alonso S, Alperi M, Fernandez M, Sarasqueta C (2011) Stratification by age of onset with 30 years as age limit is an effective means of identifying PSORS1-associated psoriasis in patients with psoriatic arthritis. Joint Bone Spine 78(6):581\u2013583. https:\/\/doi.org\/10.1016\/j.jbspin.2011.02.009","journal-title":"Joint Bone Spine"},{"issue":"4","key":"4083_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/tpj.2015.53","volume":"16","author":"T Cabaleiro","year":"2016","unstructured":"Cabaleiro T, Prieto-Perez R, Navarro R et al (2016) Paradoxical psoriasiform reactions to anti-TNFalpha drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenomics J 16(4):336\u2013340. https:\/\/doi.org\/10.1038\/tpj.2015.53","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"4083_CR37","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1365-2133.2012.10992.x","volume":"167","author":"JG Bergboer","year":"2012","unstructured":"Bergboer JG, Oostveen AM, de Jager ME et al (2012) Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-C*06. Br J Dermatol 167(4):922\u2013925. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10992.x","journal-title":"Br J Dermatol"},{"key":"4083_CR38","doi-asserted-by":"publisher","first-page":"101879","DOI":"10.1155\/2015\/101879","volume":"2015","author":"R Prieto-Perez","year":"2015","unstructured":"Prieto-Perez R, Solano-Lopez G, Cabaleiro T et al (2015) Polymorphisms associated with age at onset in patients with moderate-to-severe plaque psoriasis. J Immunol Res 2015:101879. https:\/\/doi.org\/10.1155\/2015\/101879","journal-title":"J Immunol Res"},{"issue":"3","key":"4083_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.semarthrit.2012.05.006","volume":"42","author":"MT Nguyen","year":"2012","unstructured":"Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME (2012) The SAPHO syndrome. Semin Arthritis Rheum 42(3):254\u2013265. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.05.006","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4083-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4083-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4083-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T22:02:48Z","timestamp":1693605768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4083-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4083"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4083-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"7 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Peking Union Medical College Hospital, Peking Union Medical College, and Chinese Academy of Medical Sciences (ethics documents number ZS-944). All individual participants provided written informed consent to participate in this cohort at the time of inclusion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}